Core Viewpoint - ST Xiangxue's subsidiary, Xiangxue Life Science, has received clinical trial approval for its new drug XLS-103 injection from the National Medical Products Administration, marking a significant milestone in its TCR T-cell therapy development [1] Group 1 - Xiangxue Life Science has obtained two clinical trial approval notices for XLS-103 injection, with notification numbers 2025LP03514 and 2025LP03515 [1] - The approval of XLS-103 injection is the sixth and seventh clinical trial notices related to TCR-T products developed by Xiangxue Life Science [1]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Core Viewpoint - The company has entered into a computer chip sales agreement with Hong Kong Nanjiguang Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Nanjiguang Electronic Technology Co., Ltd., for the supply of integrated circuit (IC) chips totaling 1.61 million units, valued at approximately $19.95 million (around HKD 156 million) [1] Group 1 - The agreement is part of the company's routine business operations and aims to expand its product portfolio in the computer equipment sector [1] - The company is committed to seeking business developments that enhance long-term shareholder value [1]

Core Viewpoint - International Commercial Settlement (00147.HK) announced a computer chip sales agreement with Shenzhen Nanjiguang Electronics Technology Co., Ltd. (stock code: 300940.SZ) through its wholly-owned subsidiary Hong Kong Nanjiguang Technology Co., Ltd. on December 5, 2025 [1] Group 1 - The agreement involves the sale of computer chips [1] - The partnership is expected to enhance the technological capabilities of the involved companies [1] - The agreement signifies a strategic move in the semiconductor market [1]

Core Viewpoint - International Commercial Settlement (00147.HK) has entered into a computer chip sales agreement with Hong Kong Nanjiguang Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Nanjiguang Electronics Technology Co., Ltd. (300940.SZ), for the supply of integrated circuit (IC) chips totaling 1,610,000 units, valued at approximately $19.95 million (around HKD 156 million) [1] Group 1 - The agreement is set to be executed by December 5, 2025, indicating a long-term commitment to the supply of IC chips [1] - The total contract value of approximately $19.95 million reflects the company's strategic move to expand its product portfolio in the computer equipment business [1] - The board believes that the transaction under the chip sales agreement is part of the company's routine and general business operations, aiming to capitalize on growth opportunities in the IC chip market [1]

Core Viewpoint - International Commercial Settlement (00147) has entered into a computer chip sales agreement with Hong Kong Nanjiguang Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Nanjiguang Electronics Technology Co., Ltd., for the supply of 1.61 million integrated circuit (IC) chips valued at approximately $19.95 million (around HKD 156 million) [1]. Group 1 - The agreement is set to be executed on December 5, 2025, and is part of the company's routine business operations [1]. - The chip sales agreement expands the company's product portfolio in the computer equipment business [1]. - The company is committed to seeking business developments that enhance long-term shareholder value [1].

Core Viewpoint - International Commercial Settlement (00147.HK) has entered into a computer chip sales agreement with Hong Kong Nanjiguang Technology Co., Ltd., a wholly-owned subsidiary of Shenzhen Nanjiguang Electronic Technology Co., Ltd. The agreement involves the supply of 1,610,000 integrated circuit (IC) chips valued at approximately $19.95 million (around HKD 156 million) [1]. Group 1 - The agreement is set to be executed by December 5, 2025, indicating a long-term commitment to the partnership [1]. - The total contract value of approximately $19.95 million reflects the company's strategic move to expand its product portfolio in the computer equipment business [1]. - The board believes that the transaction under the computer chip sales agreement is part of the company's routine and general business operations, aiming to capitalize on growth opportunities in the IC chip market [1].

本公佈乃由國際商業結算控股有限公司（「本公司」）自願作出，以向本公司股東（「股東」）及本 公司潛在投資者提供有關本公司及其附屬公司（「本集團」）業務發展之最新情況。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年十二月五日，本集團與深圳市南 極光電子科技股份有限公司（股份代號：300940.SZ）的全資附屬公司香港南極光科技有限公司 （「香港南極光」）訂立計算機芯片銷售協議（「計算機芯片銷售協議」）。 根據計算機芯片銷售協議，本集團同意供應，而香港南極光同意採購集成電路(IC)芯片合共 1,610,000件。合約總值為約19,950,000美元（相當於約155,640,000港元）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性或完整性亦不發 表任何聲明，且表明不會就因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責任。 除非本公佈另有規定，否則本公佈中美元兌港元採用匯率1.00美元兌7.8港元。 INTERNATIONAL BUSINESS SETTLEMENT HOLDINGS LIMITED 國際商業結算控股有限公 司 （於百 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 國際商業結算控股有限公司 （於百慕達註冊成立之有限公司） 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00147 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 498,000,000,000 | HKD | | 0.001 HKD | | 498,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 498,000,000,000 | HKD | | 0.001 HKD | | 498,000, ...

国际商业结算(00147)发布截至2025年9月30日止六个月业绩，该集团期内取得收入3839.6万港元，同比 减少64.07%;公司拥有人应占亏损7291.3万港元，同比扩大52.7%;每股基本亏损0.36港仙。 ...